Journal
CANCERS
Volume 11, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/cancers11020186
Keywords
oncolytic virotherapy; cancer immunotherapy; glioblastoma
Categories
Funding
- Swedish Cancer Society [CAN 2016/318]
- Swedish Children Cancer Foundation [PR2015-0049]
- Swedish Research Council [2015-03688]
- Swedish Research Council [2015-03688] Funding Source: Swedish Research Council
Ask authors/readers for more resources
Glioblastoma (GBM) is the most common type of primary brain tumor in adults. Despite recent advances in cancer therapy, including the breakthrough of immunotherapy, the prognosis of GBM patients remains dismal. One of the new promising ways to therapeutically tackle the immunosuppressive GBM microenvironment is the use of engineered viruses that kill tumor cells via direct oncolysis and via stimulation of antitumor immune responses. In this review, we focus on recently published results of phase I/II clinical trials with different oncolytic viruses and the new interesting findings in preclinical models. From syngeneic preclinical GBM models, it seems evident that oncolytic virus-mediated destruction of GBM tissue coupled with strong adjuvant effect, provided by the robust stimulation of innate antiviral immune responses and adaptive anti-tumor T cell responses, can be harnessed as potent immunotherapy against GBM. Although clinical testing of oncolytic viruses against GBM is at an early stage, the promising results from these trials give hope for the effective treatment of GBM in the near future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available